Nitric oxide synthase gene therapy - GenVec

Drug Profile

Nitric oxide synthase gene therapy - GenVec

Alternative Names: Genstent; iNOS gene therapy - GenVec

Latest Information Update: 29 Jun 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GenVec
  • Class Gene therapies
  • Mechanism of Action Nitric oxide synthase stimulants; Nitric oxide synthase type II inhibitors; Nitric oxide synthase type II modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Vascular graft occlusion; Vascular restenosis

Most Recent Events

  • 16 Jun 2017 GenVec was acquired by Intrexon Corporation
  • 18 Mar 2003 Discontinued - Preclinical for Vascular graft occlusion in USA (Intra-arterial)
  • 18 Mar 2003 Discontinued - Preclinical for Vascular restenosis in USA (Intra-arterial)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top